Trastuzumab emtansine in advanced HER2-positive breast cancer

Community Oncology

Volumn 10, Issue 3, 2013, Pages 71-73

  Abraham, Jame ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB EMTANSINE;

ARTICLE; BREAST CANCER; FOLLOW UP; HUMAN;

EID: 84900300910     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Hurvitz SA, Kakkar R. The potential for T-DM1 in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol. 2012;4: 235-245.
2. Blackwell KL, Miles D, Gianni L, et al. Primary results from EMILIA, a phase III study of T-DM1 (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane [ASCO abstract LBA1]. http://www. asco.org/ASCOv2/Meetings/Abstracts?&vmview-abst-detail-view &confID-114&abstractID-98675. Accessed February 26, 2013.